Desvenlafaxine combined conventional therapy
PreclinicalSmall molecule
Desvenlafaxine combined conventional therapy is one of 15 small molecule programs targeting Herpes Zoster. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Herpes Zoster
#DrugCompanyPhaseTrials
1Famvir
NovartisApproved
Zovirax
BBp Consulting, Inc
Approved
Foscavir
CClinigen, Inc.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Neurontin
VViatris Specialty LLC
Approved
Recombinant Herpes Zoster Vaccine
BBeijing Luzhu Biotechnology Co., Ltd.
Phase 3
Vimpat
UCBPreclinical
Shingrix
SShenzhen Shenxin Biotechnology Co., Ltd
Phase 1
HZ Vaccine (IN001)
SShenzhen Shenxin Biotechnology Co., Ltd
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Herpes Zoster1 trial
The Analgesic Efficacy and Safety of Desvenlafaxine in Patients With Herpes Zoster
Recruiting·—·N/A·NCT07361809·750 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBeijing Tiantan Hospital